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Aims Low-grade chronic inflammation characterizes obesity and metabolic syndrome. Here, we aim at investigating the
impact of the acute-phase protein long pentraxin 3 (PTX3) on the immune-inflammatory response occurring during
diet-induced obesity.
....................................................................................................................................................................................................
Methods
and results
PTX3 deficiency in mice fed a high-fat diet for 20 weeks protects from weight gain and adipose tissue deposition
in visceral and subcutaneous depots. This effect is not related to changes in glucose homeostasis and lipid metab-
olism but is associated with an improved immune cell phenotype in the adipose tissue of Ptx3 deficient animals,
which is characterized by M2-macrophages polarization and increased angiogenesis. These findings are recapitu-
lated in humans where carriers of a PTX3 haplotype (PTX3 h2/h2 haplotype), resulting in lower PTX3 plasma lev-
els, presented with a reduced prevalence of obesity and decreased abdominal adiposity compared with non-
carriers.
....................................................................................................................................................................................................
Conclusion Our results support a critical role for PTX3 in the onset of obesity by promoting inflammation and limiting adipose
tissue vascularization and delineate PTX3 targeting as a valuable strategy for the treatment of adipose tissue-
associated inflammatory response.
                                                                                                                                                                                                                   
Keywords Pentraxin 3 • Inflammed adipose tissue • Immunometabolism
1. Introduction
Obesity is an epidemic condition leading to health complications such as dia-
betes and cardiovascular diseases.1 Obesity, which is frequently the conse-
quence of nutrient excess and loss of metabolic homeostasis, contributes to
a state of chronic low-grade inflammation,2 which results in an increase of
systemic pro-inflammatory mediators and the switch of adipose tissue resi-
dent immune cells from a tolerogenic to a pro-inflammatory phenotype.3
Adipose tissue-resident immune cells, once activated, produce adipokines
and cytokines, including tumour necrosis factor a (TNFa), interleukin-1b
(IL-1b), interleukin-6 (IL-6), and C-C Motif Chemokine Ligand 2 (Ccl2), thus
supporting the recruitment of new immune cells that perpetuate the local
and systemic state of inflammation.4,5 Although increased circulating levels
of C-reactive protein (CRP) parallels the development of obesity and meta-
bolic syndrome,6 the behaviour of other acute phase proteins, as the long
pentraxin 3 (PTX3), in such conditions is still elusive.
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PTX3 is a homo-octameric secreted glycoprotein which shares the C-
terminal domain with CRP and serum amyloid P component (both short
pentraxins), and possesses a unique and unrelated N-terminal
domain, which accounts for PTX3-specific functions.7 Similar to CRP, PTX3
is induced by inflammatory signals, such as IL-1b,7 TNFa,8 and
microbe-associate molecular patterns,9 but synthetized by several cells
types, including myeloid-derived cells,10 vascular endothelial cells,11 smooth
muscle cells,12 and also adipocytes.8 PTX3 activates innate immune
responses by interacting with some pathogen moieties and complement
components (C1q, Ficolins, Factor H),13 thus promoting the phagocytosis of
some microorganism, and tuning inflammatory responses. Moreover, PTX3
modulate vascular biology by dampening neutrophils recruitment to inflam-
matory sites14 and reactivity through P-selectin binding,15 reducing arterial
thrombosis,16 atherosclerosis,17 and the size of myocardial infarction.18
In humans, PTX3 plasma levels rapidly increase few hours after myo-
cardial infarction19 and are an independent predictor of 3-month mortal-
ity.20 More recently, increased PTX3 plasma levels have been associated
with multifactorial inflammatory diseases, including endothelial dysfunc-
tion and advanced vascular inflammation in diabetes,21 non-alcoholic
fatty liver disease,22 and chronic kidney disease.23
Genetically obese (ob/ob) and obese-diabetic (db/db) mice present
higher levels of Ptx3 mRNA in visceral adipose tissue (VAT) compared
with lean mice, an effect consistent with increased levels of TNFa.8 In
humans, PTX3 is produced by adipocytes in VAT and subcutaneous adi-
pose tissue (SCAT)24,25 and its levels in VAT have been associated with
macrophages infiltration in obese subjects but not in controls.24 These
findings are reflected in the direct association of PTX3 plasma levels with
metabolic syndrome26 and obesity27 a finding that however is not consis-
tent in all cohorts.28,29
Thus to elucidate whether PTX3, a key molecule linking innate immu-
nity, inflammation and obesity,24,30,31 represents a bystander or plays an
active role in the immunoinflammatory response observed during obe-
sity, we profiled the immunoinflammatory and metabolic response to an
obesogenic diet of Ptx3-/- compared with wild type (WT) littermates and
investigated in humans the impact of a PTX3 haplotype32–34 on ectopic
fat deposition and metabolic status.
2. Methods
2.1 Animals
WT and Ptx3-/- male mice littermates on the C57BL/6 genetic back-
ground were bred in house and generated as in detail described previ-
ously.35 C57BL/6 WT mice for the first crossings were from Charles
River Italy. Homozygous mutant mice display female subfertility due to
abnormalities of the cumulus oophorus and are susceptible to invasive
pulmonary aspergillosis associated with defective recognition of conidia
by alveolar macrophages and dendritic cells and impaired induction of
adaptive Type 2 responses (http://www.informatics.jax.org/marker/
MGI:104641). Eight-week old mice were housed four per cages and kept
in a temperature-controlled environment (20 ± 2C, 50± 5% relative
humidity) with a 12-h light/dark cycle in an air-conditioned room and
free access to food and water. Starting from 8 weeks of age, male litter-
mates WT and Ptx3-/- mice were randomized in two groups, one fed a
standard fat diet (SFD, 10% Kcal from fat, Research diet INC,
Cat#D12450H), and one an high-fat diet (HFD, 45% Kcal from fat,
Research diet INC, Cat#D12451). Food intake and weight gain were
measured weakly. Mice were sacrificed at 20 weeks, after isoflurane (2%)
inhalation and cervical dislocation, and VAT, SCAT, brown adipose
tissue (BAT), liver, and blood were collected and weighted. All animal
procedures performed conform to the guidelines from directive 2010/
63/EU of the European Parliament on the protection of animals used for
scientific purposes and were approved by the Ethical Committee
(Progetto di Ricerca 2012/02, Autorizzazione Ministeriale 811/2017).
2.2 Magnetic resonance for imaging
Magnetic resonance for imaging (MRI) was used to evaluate VAT, SCAT,
and BAT depots in WT and Ptx3-/- mice on HFD diet. For this procedure,
mice were anaesthetized with 2% isoflurane. Consecutive photos at the
level of shoulder blades, chest, and abdomen of each mouse were ac-
quired and subsequently analysed with PhotoshopVR software for the
quantification of adipose tissue deposition.
2.3 Glucose and insulin tolerance test
Intraperitoneal glucose tolerance test (IP-GTT) and insulin tolerance test
(ITT) were used to measure plasmatic clearance of glucose after intra-
peritoneal injection of glucose or insulin respectively. In brief, animals
were fasted overnight (approximately 14 h), then blood glucose levels at
fasting and after 15, 30, 60, 90, and 120 min from injection of glucose solu-
tion (20% w/v in PBS, 2 mg per grams of body weight) were measured
with a glucometer (ONE-TOUCH Ultra glucometer). For ITT, the ani-
mals were fasted for 4 h. Glucose plasma levels were measured at fasting
and after 15, 30, 60, 90, and 120 min from injection of human recombinant
insulin (1 mU per gram of body weight, Humulin R100 Ul/mL).
2.4 Samples preparation for
immunophenotyping by flow cytometry
Fresh collected blood was stained (50mL) after the lysis of red blood
cells with ACK solution (KHCO3 10 mM, NH4Cl 150 mM, EDTA
0.1 mM) for 10 min at room temperature.
Fresh VAT and SCAT were placed on ice in a six well plate and cut in
small pieces in 2 mL of PBS 5% BSA solution, then collagenase (2 mg/mL
final concentration, NB4 standard grade, Serva) and CaCl2 (5 mM final
concentration) were added and samples were incubated at 37C for
40 min under agitation. Samples were then top up with MACS (PBS, 2%
FCS, 2 mM EDTA) and filtered on a sterile bandage and subsequently on
a 100lm and 70lm cells strainer. After the lysis of red blood cells with
ACK for 5 min on ice, samples were washed, spin and resuspended in
50mL of antibodies mix (Supplementary material online, Table S1). All
flow cytometry antibodies were used at 1:100 dilutions unless otherwise
specified, optimal antibody concentrations for staining were calculated
based on manufacturer instructions.
For immunophenotyping a cell suspension containing 1 106 cells or
50mL of blood were acquired with FACS Calibur (BD Bioscience) or
Novocyte 3000 (ACEA Biosciences). Cell sorting was performed with
FACSAria II flow cytometer (BD Bioscience). Antibodies used are listed
in the Supplementary material online, Table S1.
2.5 Blood biochemistry measurements
Blood samples were collected in EDTA tubes by tail vein at 10 weeks
and intracardiac puncture at 20 weeks and plasma was separated by cen-
trifugation (8000 rcf for 10 min) at 4C.
Total plasma cholesterol and triglycerides were measured from fro-
zen plasma by standard enzymatic techniques using the Cholesterol CP
KIT (ABX Pentra, HORIBA Medical) or the triglyceride CP KIT (ABX
Pentra, HORIBA Medical). Cholesterol and triglyceride concentration
were read by spectrophotometer at 490 nm (Bio-Rad iMark microplate
1862 F. Bonacina et al.
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reader). Plasma insulin concentrations were quantified using mouse
Ultrasensitive ELISA kit (Mercodia).
PTX3 plasma levels in human blood samples at enrolment were
determined as previously described36 with sandwich ELISA (detection
limit 0.1 ng/mL, inter-assay variability from 8% to 10%) developed in-
house, by personnel blind to patients’ characteristics. Data are reported
as ng/mL.
2.6 Histology
Part of the VAT and SCAT was fixed overnight in 4% buffer formalin
(Sigma-Aldrich), embedded in paraffin and tissue section (5lm) stained
with haematoxylin and eosin (Sigma-Aldrich). Haematoxylin/eosin
stained sections from the adipose tissue of each animal were acquired
using the axiovision Zeiss software (a field of 0.2 mm2 at 10 of magnifi-
cation). Quantification of adipocytes areas was performed using Adobe
Photoshop software: an area with intact adipocytes was manually se-
lected, then the calculated area (1 pixel = 0.6289 micron) was divided
for the number of adipocytes counted in that selected area (at least four
independent measurement per mouse). Crown-like structures were
counted from eight visceral sections per mouse (n= 6) by an operator
blinded of the genotypes.
Immunofluorescence analysis of WT and Ptx3-/- VAT were performed
by staining with F4/80 antibody (Biolegend), to identify crown-like struc-
ture, and CD31 antibody (Abcam) for the identification of the
vasculature.
2.7 Quantitative real time PCR (qRT-PCR)
Total RNA from cells and VAT was isolated using Nucleo Spin RNA kit
(Machery NAGEL) and RNAsi Lipid Tissue Mini kit (QIAGEN), respec-
tively, as indicated in the manufacturer instruction.
RNA assessed for quality and quantity using absorption measure-
ments (NanoDropTM 1000 Spectrophotometer, Thermo Fisher
Scientific) and reverse transcribed into cDNA (400 ng RNA) with
iScriptTM cDNA synthesis kit (BioRad). Gene expression analysis was
performed with SYBR Green Supermix (ThermoFisher Scientific) in
CFX connect light cycler (BioRad, Cat#1708841). Expression was calcu-
lated using the DDCt method (Livak and Schmittgen, 2001) and normal-
ized to a housekeeping gene (Rpl, L Ribosomal Protein). Primers for
qPCR were designed with the help of online tools (https://www.eurofins
genomics.eu/). The thermal cycling profile was a two-step amplification
(95C for 5 min, followed by 45 cycles of 95C for 10 s and 55C for
30 s). The sequences of the qPCR Primers are reported in the
Supplementary material online, Table S2.
2.8 Immunoblotting
Adipose tissue was homogenized in RIPA buffer (0.1% sodium dodecyl
sulfate, 0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, and
50 mM Tris HCl, pH 8.0, supplemented with protease inhibitors).
Tissues were lysed at 4C for 15 min and clarified by centrifugation at
12 000 rcf. Lysates were separated by SDS-PAGE transferred to nitro-
cellulose and immunoblot with primary antibody (anti-VEGF ‘Vascular
Endothelial Growth Factor’ Biorbyt orb256347, anti-CD31 ‘Cluster of
Differentiation 31’ Cell Signaling 77699 and anti-a Tubulin, Sigma-Adrich
T5168) followed by HRP-conjugated secondary antibodies. HRP activity
was identify by enhanced chemiluminescence (Clarity Western ECL,
BioRad) and Odyssey Imaging System.
2.9 In vitro macrophages differentiation
Murine bone marrow-derived macrophages (BMDM) were generated
collecting cells from both mouse femurs. Red blood cells from this prep-
aration were lysed with 100mL ACK solution for 2 min at room temper-
ature. The cells were then cultured 24 h on 75 cm2 culture flask. Non-
adherent cells (2.5  106 cells/well) were cultured in a 12 wells plate,
6 days in D-MEM, 10% FBS with 20 ng/mL recombinant murine (rm) M-
CSF (Peprotech) changing the medium every 3 days. One day before po-
larization, growth medium was replaced by D-MEM, 10% FBS. Cells
were cultured for 6 h with 100 ng/mL LPS purified from Escherichia coli
055:B5 (sigma-Aldrich) plus 20 ng/mL rmIFNg (Peprotech) for M1 polari-
zation, 20 ng/mL rmIL-4 (Peprotech) to induce M2 polarization or only
in D-MEM, 10% FBS, M0 condition. Human recombinant PTX3 was used
at 200 ng/mL.
2.10 Human study—anthropometric
measurements
Measurements of body composition and regional adipose tissue distribu-
tion was performed via dual-energy X-ray absorptiometry (DEXA), as
previously described,37 using a Lunar iDXA (Ge Healthcare, Madison,
WI, USA). Scans were then analysed through enCORE software (version
14.0), in order to set regions of interest for detection and quantification,
discriminating among bone mass (calculating density as well), lean and ad-
ipose tissue. Android fat was computed automatically over the android
region, a region-of-interest automatically defined by the enCORE soft-
ware, whose caudal limit is automatically placed at the top of the iliac
crest and whose height is set to 20% of the distance from the top of the
iliac crest to the base of the skull to define its cephalad limit. The investi-
gation is conform to the principles outlined in the Declaration of
Helsinki. Each subject signed the informed consent for the collection of
blood samples and clinical data for research purposes prior to the inclu-
sion in the study.
2.11 Statistical analysis
Statistical analysis was performed using Prism (GraphPad) and SPSS v.23
(IBM Corp., Chicago, IL, USA) for human data. Both mice and human
data are expressed as mean ± SEM and a P-value of less than 0.05 was
considered significant (*P< 0.05, **P< 0.01, and ***P< 0.001). For com-
parison between two groups an unpaired two-sides test with a 95% con-
fidence interval was used. In detail, for groups with more than seven
observations, after checking for the normal distribution of data, a para-
metric Student’s t-test was applied, whereas for groups with less than six
observations or not normally distributed a Mann–Whitney non-
parametric test was used, as also indicated in the figure legends. For hu-
man data, Mann–Whitney and Kolmogorov–Smirnov non-parametric test
were used to compare anthropometric variables and plasma PTX3 levels
after testing the distribution of the groups using the Shapiro–Wilk test.
3. Results
3.1 PTX3 level increases during high-fat
diet feeding and supports the development
of obesity
Adipose tissue expansion associates with a worsening of the inflamma-
tory status both locally and systemically.38 Therefore, we first investi-
gated whether plasma levels of PTX3 change during the onset of obesity,
as an index of innate response activation. To this aim, WT mice were fed
Immunoinflammatory role of PTX3 during obesity 1863
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a HFD or a SFD for 20 weeks. As expected, HFD-fed mice showed in-
creased body weight and increased VAT and SCAT deposition
(Supplementary material online, Figure S1A and B). Moreover, HFD-fed
mice displayed an impaired glucose tolerance and insulin sensitivity as
assessed by GTT and ITT (Supplementary material online, Figure S1C and
D). HFD mice also presented an increased infiltration of monocytes and
macrophages into the VAT, which associated to increased Ccl2 and Cd68
mRNA expression (Supplementary material online, Figure S1E and F). In
agreement with the increased immune-inflammatory profile, PTX3
plasma levels were also significantly increased after 10 and 20 weeks of
HFD feeding compared with SFD feeding (Figure 1A).
This observation prompted us to investigate whether PTX3 plays a
causal role or simply reflects the underlying inflammatory response asso-
ciated to obesity. Therefore, WT and Ptx3-/- mice were fed up to
20 weeks with HFD. PTX3 deficiency was associated with significant re-
duced weight gain compared with WT (Figure 1B), in spite of a similar
daily food intake (Supplementary material online, Figure S2A). This phe-
notype was confirmed by MRI analysis showing a reduced VAT and
SCAT deposition at both 10 and 20 weeks of HFD in Ptx3-/- mice com-
pared with WT mice (Figure 1C–E); whereas the amount of BAT in the
intrascapular area was similar between the two experimental groups
(Figure 1E and Supplementary material online, Figure S2B and C). At sacri-
fice, the amount of VAT and SCAT but not of BAT was significantly re-
duced in Ptx3-/- mice compared with WT mice. Similar weights for liver,
pancreas, and spleen were also observed (Figure 1E).
These data suggest that PTX3 plays a non-redundant role during
HFD-induced obesity and brought us to explore whether the phenotype
observed might have been the consequence of impaired glucose metab-
olism. To this end, we measured basal glycaemia following overnight fast-
ing and performed an intraperitoneal glucose (IP-GTT) and ITT in WT
and Ptx3-/- mice after 10 and 20 weeks of diet. Basal glycaemia was similar
between WT and Ptx3-/- mice following 10-week or 20-week of HFD
(WT 121± 10 mg/dL, Ptx3-/- 111± 9 mg/dL at 10 weeks; WT
145 ± 13 mg/dL, Ptx3-/- 130 ± 3 mg/dL at 20 weeks, respectively), as were
glucose curves over time after IP-GTT or ITT (Figure 2A–D). Likewise,
plasma insulin levels and lipid profile were not different between Ptx3-/-
and WT mice after 20-week HFD (Figure 2E–G). Similarly, data collected
in mice fed a SFD showed a comparable metabolic profile (analysis of
body weight, glucose, and insulin tolerance) between WT and Ptx3-/-
mice (Supplementary material online, Figure S3A–E).
A
C D E
B
Figure 1 PTX3 is implicated in diet-induced obesity. (A) Plasma PTX3 levels measured at 10 weeks (n= 4–5 per group) and 20 weeks (n= 12–13 per
group) after the starting of the high-fat diet (HFD) in C57BL/6 mice. (B) Weight gain of WT and Ptx3-/- mice on HFD measured weekly and area under
the curve (AUC) of weight gain, n= 7 per group. (C) Visceral (VAT) and subcutaneous (SCAT) adipose tissues in WT and Ptx3-/- mice on HFD evaluated
by magnetic resonance imaging (MRI). Analysis was performed at 10 weeks (left) and 20 weeks (right) of HFD feeding, n= 5 per group. (D)
Representative pictures of magnetic resonance imaging of data presented in C. (E) Percentage of organ weight compared with final body weight at 20
week HFD, n= 6–7 per group. Data are presented as mean ± SEM. Statistical analysis was performed with Student’s t-test (A, B, F) or Mann–Whitney test
(A, C, E), *P< 0.05, **P< 0.01.
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..All together these results ruled out that a conserved glucose and lipid
homeostasis explains the phenotype of Ptx3-/- mice, and therefore, point
to other mechanisms of protection to HFD-induced obesity.
3.2 PTX3 deficiency promotes
pro-resolution macrophage skewing
Next, we investigated whether the decreased weight gain and fat accumu-
lation might have been related to a different inflammatory profile in Ptx3-/-
mice. First, we profiled circulating immune cell signature in Ptx3-/- and WT
mice on HFD (Figure 3). A significant decrease in the number of circulating
neutrophils was observed (457 ± 39 cells/lL and 350 ± 35 cells/lL for
WT and Ptx3-/- mice, respectively, P< 0.05; Figure 3B), while the absolute
count of blood monocytes was similar between WT and Ptx3-/- fed a HFD
(322 ± 36 cells/lL and 266 ± 36 cells/lL for WT and Ptx3-/- mice, respec-
tively, data not shown) as was the case for monocytes subsets distribution
(Figure 3C). The number of circulating CD3þ T and CD19þ B lymphocytes
(CD3þ: WT = 741 ± 196 cells/lL and KO = 643 ± 115 cells/lL; CD19þ:
WT = 3040 ± 656 cells/lL and KO = 2495 ± 403 cells/lL, data not
shown) and distribution of the different CD4þ and CD8þ T cells subsets
(Tnaive, Tcentral and effector memory, T effector cells) was also similar
between WT and Ptx3-/- mice (Figure 3D–G). A similar immune profile was
observed in Ptx3-/- and WT mice fed a SFD (Supplementary material on-
line, Figure S4A–G).
Despite of a similar circulating leucocytes frequency, the analysis of
the inflammatory profile in the VAT and SCAT of HFD-fed Ptx3-/- mice
showed a decreased expression of markers associated with inflamma-
tion, such as Ccl2 and Il6, compared with WT mice (Figure 4A and
Supplementary material online, Figure S5A). This profile was associated
with a significant reduction in the number of monocytes, macrophages,
and neutrophils that accumulate in the VAT of Ptx3-/- mice compared
with WT (Figure 4B, see also Supplementary material online, Figure S6 for
A B
C
E F G
D
Figure 2 PTX3 deficiency does not affect glucose homeostasis and lipid metabolism during diet-induced obesity. (A and B) Glucose tolerance test
(GTT) performed at 10 (A) and 20 (B) weeks of HFD feeding in WT and Ptx3-/- mice, n= 5 per group. Glycaemia was measured before i.p. glucose injec-
tion (t = 0, baseline values) and after 15, 30, 60, 90, and 120 min. (C and D) Insulin tolerance test (ITT) performed at 10 (C) and 20 (D) weeks of HFD feed-
ing in WT and PTX3 KO mice, n= 5 per group. Glycaemia was measured before i.p. insulin injection (t = 0, baseline values) and after 20, 40, 60, and 120
min. (E–G) Insulin (E), cholesterol (F), and triglycerides (G) plasma concentrations in WT and PTX3 plasma, n= 6–8 per group. Data are presented as
mean ± SEM. Statistical analysis was performed with Student’s t-test (E) or Mann–Whitney test (A–D, F, G).
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gating strategy). Differently, only macrophage number was reduced in
SCAT of Ptx3-/- mice compared with WT (Supplementary material on-
line, Figure S5B). In addition, the phenotypic characterization of mono-
cytes and macrophages isolated from the VAT revealed that monocytes
from Ptx3-/- VAT presented a reduced expression of Ccr2 (CCL2 recep-
tor) but not of Cx3cr1 (CX3CL1 or Fractalkine receptor, marker highly
expressed on alternative activated monocytes) compared with WT
(Figure 4C), pointing towards a pro-resolving profile of monocytes. In
parallel, Ptx3-/- VAT macrophages presented a significant increased ex-
pression of Arg1 (Arginase 1) and Ym1 (M2-like molecules) compared
with WT macrophages (Figure 4D). This difference was specific for VAT
macrophages but not for macrophages infiltrating the SCAT
(Supplementary material online, Figure S5C). Next, we assessed whether
PTX3 affects macrophage polarization. Ptx3-/- M0 BMDM, present an in-
creased expression of Ym1, Arg1, and Ifng (Figure 4E); incubation of M1
BMDM from WT and Ptx3-/- mice with recombinant PTX3 results in in-
creased expression of Il6 and a decrease of Ym1 and Cd206 expression
(Figure 4F). These data further support the ability of PTX3 to sustain an
M1 response.
In agreement with the reduced inflammatory profile, macrophage
count, and consequently, the frequency of crown-like structures sur-
rounding dying or dead adipocytes, where macrophages resorb the rem-
nants of these dying cells,39 was significantly decreased in Ptx3-/- VAT
(Figure 4G and H and Supplementary material online, Figure S7). These
results suggest that PTX3 deficiency associates with lower monocytes
recruitment and macrophages M1-polarization in VAT.
3.3 Enhanced vascularization limits visceral
adipose hypertrophy in Ptx3/mice
Obesity associates with hypertrophic visceral adipocytes that, undergo-
ing cell death, promote an inflammatory response.38 Physiological adi-
pose tissue expansion is controlled by the rate of vascularization and
angiogenesis that plays a crucial role favouring a correct oxygen supply
A
D
E F G
B C
Figure 3 Protection to HFD-induced obesity of Ptx3-/- mice is not the consequence of a different circulating immune signature. (A) Gating strategy for
the identification of monocytes (CD11bþLy6CþLy6G-) and neutrophils (CD11bþLy6Gþ) in the blood of WT and Ptx3-/- mice from flow cytometry
analysis. (B) Neutrophils/mL of blood in WT and Ptx3-/- mice on HFD, n= 4 per group. (C) Analysis of monocytes subsets in blood of WT and Ptx3-/- mice
on HFD, n= 11–12 per group. (D) Gating strategy for the identification of B cells (CD19þCD3-), T cells (CD19-CD3þ, T helper CD4þ, T cytotoxic
CD8þ), and T cells subsets in blood of WT and Ptx3-/- mice (T naive—Tn CD62LþCD44-, T effector memory—Tem CD62-CD44þ, T central mem-
ory—Tcm CD62LþCD44þ, T effector—Teff CD62-CD44-) from flowcytometry analysis. (D–F) Percentages of CD4þ (E) and CD8þ (F) T lympho-
cytes and their subsets (G) in blood of WT and Ptx3-/- mice, n= 11 per group. Data are presented as mean ± SEM. Statistical analysis was performed with
Student’s t-test (C, E–G) or Mann–Whitney test (B).
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to adipocytes. Accordingly, we found that adipocytes from Ptx3-/- VAT
(Figure 5A) and SCAT (Supplementary material online, Figure S8A)
displayed a reduced hypertrophy compared with WT mice. Given the
anti-angiogenetic role of PTX3, accomplished by binding and thus inhibit-
ing fibroblast growth factor 2 (FGF2),40,41 we investigated whether
PTX3 deficiency impairs adipose tissue vascularization, assessing the ex-
pression of key markers of angiogenesis. As shown in Figure 5B Cd31 and
Vegfa (vascular endothelial growth factor a), mRNA expression was sig-
nificantly increased in VAT from Ptx3-/- compared with that from WT
mice. Concordantly, VEGFA protein expression and VAT vascularization
were increased in Ptx3-/- mice compared with WT animals (Figure 5C–F).
This effect appeared to be independent of macrophage-derived VEGF as
its expression was similar in M0, M1 or M2 macrophages from WT or
Ptx3-/- BMDM (Supplementary material online, Figure S8B). In addition,
A
E
G H
F
B C D
Figure 4 PTX3 deficiency is associated with reduced inflammation and innate immune cells recruitment in VAT. (A) mRNA expression relative to Rpl
(L Ribosomal Protein) of inflammatory genes in VAT of WT and Ptx3-/- mice on 20-week HFD, n= 5–10 per group. (B) Numbers corrected for tissue
weight of sorted monocytes (mono), macrophages (mac), and neutrophils (neutro) in VAT, n= 9–10 per group, of WT and Ptx3-/- on 20-week HFD.
(C and D) mRNA expression relative to Rpl in monocytes (C) and macrophages (D) sorted from VAT of WT and Ptx3-/- mice on 20-week HFD, n= 3–5
per group. (E) mRNA expression relative to Rpl (L Ribosomal Protein) of M0, M1, and M2 macrophages from WT and Ptx3-/- mice differentiated in vitro
for 6 h, n= 5–6 per group. (F) Effect of exogenous rhPTX3 on mRNA expression in M1 BMDM from Ptx3-/- and WT mice, n= 4–8 per group.
(G) Quantification of the numbers of crown-like structures in VAT sections from WT and Ptx3-/- mice on 20-week HFD (legends: from score 1, no crown
detected, to score 5, equal or more than 4 crowns), n= 6 per group. (H) Representative images of crown-like structures in VAT of WT and Ptx3-/- mice
stained with F4/80 antibody. Data are presented as mean ± SEM. Statistical analysis was performed with Student’s t-test (A, B) or Mann–Whitney test
(A, C–F), *P< 0.05, **P< 0.01.
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the expression of angiogenic factors was similar in the SCAT of WT or
Ptx3-/- mice (Supplementary material online, Figure S8C), thus suggesting
that PTX3 deficiency results in less pronounced inflammatory profile
and enhanced angiogenesis in the VAT.
3.4 Genetic determined lower PTX3 levels
in humans relates with a reduced visceral
adipose tissue accumulation
To translate our findings in humans, we investigated whether the pres-
ence of two different haplotypes (h1/h1 vs h2/h2) on the PTX3 locus,34
which result in lower PTX3 levels, associated with a different metabolic
profile. The carriers of the h2/h2 haplotype (n= 817) showed significant
lower PTX3 plasma levels compared with subjects with the h1/h1 haplo-
type (n= 163) [h1/h1 median 3.65 ng/mL (3.13, 4.15); h2/h2 median 3.47
(3.07, 3.96)] (Figure 6A), which was associated with a significant lower
body mass index [h1/h1 median 27.45 kg/m2 (25, 30.09); h2/h2 median
26.6 kg/m2 (24.25, 29.41)] (Figure 6B). We next measured adipose tissue
accumulation by DEXA (Figure 6C) and observed that subjects with the
h2/h2 haplotype also presented a significant reduction in adipose tissue
accumulation in the android area (an index of visceral adiposity) [h1/h1
median 48.35% (42.25, 52.88); h2/h2 median 46.70% (39.65,
52.95)](Figure 6D) but a similar distribution in the gynoid area (an index
of subcutaneous adiposity) [h1/h1 median 42.30% (32.65, 52.03); h2/h2
median 44.20% (33.60, 51.90)] (Figure 6E), resulting in a significant differ-
ence in android-gynoid ratio [h1/h1 median 1.12 (0.98, 1.35); h2/h2
A
C
F
D E
B
Figure 5 Ptx3-/- mice present smaller adipocytes and an enhanced VAT vascularization. (A) Quantification of adipocyte area in VAT of WT and Ptx3-/-
on 20-week HFD, n= 6–7 per group; representative pictures of sections stained with haematoxylin and eosin are shown. (B) mRNA expression relative
to Rpl (L Ribosomal Protein) of genes related to vascularization in VAT of WT and Ptx3-/- mice on 20-week HFD, n= 6–8 per group. (C and D)
Quantification of VEGFA (C) and CD31 (D) in VAT of WT and Ptx3-/- mice on 20-week HFD, n= 5–6 per group. (E) Representative panel for VEGFA (27
kDa) and CD31 (135 kDa) western blot are shown. Data are presented as mean ± SEM. (F) Quantification of vasculature by CD31 staining in Ptx3-/- and
WT VAT. Statistical analysis was performed with Student’s t-test (B, F) or Mann–Whitney test (A, C, D), *P< 0.05, **P< 0.01.
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..median 1.06 (0.93, 1.27)] (Figure 6F). These data extended the observa-
tions in animal models supporting the relevance of PTX3 on indexes of
obesity also in humans.
4. Discussion
This work demonstrates that PTX3 deficiency reduces the development
of obesity by controlling the immunoinflammatory response and the
grade of vascularization in VAT (Figure 7). The translation to humans fur-
ther confirms that carriers of a PTX3 haplotype, whose PTX3 plasma
levels are reduced, present decreased adipose tissue accumulation.
Healthy AT behaves as a pool of ‘anti-inflammatory’, ‘pro-resolving’,
and long-lived memory immune cells.42 Excessive accumulation of fat, as
a result of over nutrition and increased circulating levels of free fatty
acids, however, prompts an inflammatory response, which is paralleled
by the infiltration of activated effector immune cells in AT,43 and by a
A
B
D E F
C
Figure 6 Carriers of the h2/h2 PTX3 haplotype present reduced PTX3 plasma levels, Body mass index (BMI), and visceral fat accumulation. (A) PTX3 plasma
levels in h1/h1 and h2/h2 subjects from the PLIC study cohort; h1/h1, n= 163, h2/h2, n= 817. (B) BMI, h1/h1 (n= 201), h2/h2 (n= 921). (C) Representative
images obtained by dual-energy X-ray absorption (DEXA) scan of two individuals of the h1/h1 and h2/h2 haplotypes carriers for PTX3. (D) Android fat mass
and (E) gynoid fat mass were evaluated by DEXA scan in the two groups, h1/h1 (n= 210), h2/h2 (n= 921). (F) Android-gynoid ration. Data are presented as
mean ± SEM, Statistical analysis was performed with Kolmogorov–Smirnov test (A), Mann–Whitney test (B, D–F), *P< 0.05, **P< 0.01.
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..systemic increased of circulating activated immune cells,44 which further
support adipose-tissue inflammation and insulin resistance. Whether this
inflammatory response follows or contributes to adipocyte hypertrophy
is still a matter of discussion, but it is recognized that the improvement of
the immunoinflammatory responses counteracts the metabolic complica-
tions associated with obesity. Indeed, deficiency of CCL2, a key chemoat-
tractant protein, reduces macrophage accumulation in adipose tissue,
insulin resistance, and hepatic steatosis associated with obesity,45 while
the blockade of the costimulatory molecule CD40 and its signalling inter-
mediates, TNF receptor-associated factors 6 (TRAF6), ameliorates insulin
resistance, and hepatosteatosis by reducing CD8þ T cell infiltration into
adipose tissue.46 Similarly, our data show that PTX3 deficiency preserves
the M2-like phenotype of adipose tissue macrophages thus preventing fat
accumulation and inflammation during HFD-induced obesity. PTX3 is a
member of the pentraxin family, soluble mediators of innate immune arm,
whose levels rapidly increase following an inflammatory insult.31 Whereas
CRP accurately reflects the inflammatory state associated to obesity,6
PTX3 appears to play a role in modulating the immune response in differ-
ent contexts31: by limiting neutrophils recruitment,14 protecting from ath-
erosclerosis17 and thrombosis,16 decreasing cardiac necrosis18 and
platelet-leucocyte aggregation after myocardial infarction,15 reducing re-
stenosis40 and fibrotic scar formation,47 and behaving as onco-suppres-
sor.48 On the other hand, PTX3 has been also involved in promoting
inflammation after intestinal ischaemia and reperfusion.49 All these eviden-
ces delineate the complex role of PTX3 that might depend on cell/tissue
origin and can be affected by the glycosylation variability of the N-terminal
domain.50
Furthermore, PTX3 deficiency was shown to result in increased M2
macrophage polarization in the context of experimental models of
mesenchymal and epithelial carcinogenesis, thus favouring protumoral
immune responses and increased tumour growth.48 PTX3 was also
demonstrated to control angiogenesis and vascularization by binding to
FGF2 and inhibiting its angiogenic function.40 Angiogenesis is a complex
process, which exerts different functions based on the physio-
pathological mechanism in which it is involved. Angiogenesis is detrimen-
tal in atherosclerosis where it contributes to plaque growth and instabil-
ity,51 while its promotion in adipose tissue by angiogenetic factors, such
as VEGF and FGF2 (secreted by both adipocytes and activated macro-
phages) favours the delivery of oxygen and nutrients to adipocytes,52
thus preventing hypoxia caused by adipocyte hypertrophy, as a conse-
quence of excessive fat accumulation.53 Moreover, a direct correlation
between VEGF expression, adipose tissue vascularization and the M2
macrophage activation was shown.54,55 Of note, maintenance of an M2
phenotype has been associated with a metabolic healthy adipose tis-
sue,56 whereas the prevalence of M1-like macrophages, primarily found
in crown-like structures (CLSs) around dying adipocytes,39 associates to
the development of an inflamed adipose tissue during obesity.
These aspects point to the hypothesis that the improved profile ob-
served in VAT from Ptx3/- mice could depend on both the prevalence of
M2 macrophages as well as increased vascularization. Indeed, we observed
that PTX3 deficiency protects from adipose tissue expansion during high
fat induced-obesity through the maintenance of an anti-inflammatory mi-
lieu, mainly as the consequence of the prevalence of M2-macrophages.
Moreover, we demonstrated that PTX3 deficiency is accompanied by in-
creased CD31 and VEGF expression in adipose tissue thus indicating the
presence of an improved vascular network which might also contribute to
reduced fat accumulation in Ptx3-/- mice. Of note, VEGF was already shown
to be a targetable strategy for the prevention of obesity promoting vessel
blood formation and M2-polarization.54 Which could be the molecular
mechanism beyond the improved M2 polarization under PTX3 deficient
conditions? PTX3, when bound to pathogens, interacts with C1q and
favours complement activation; vice versa fluid-phase PTX3 sequesters
HFD
WT
Ptx3-/-
Lean mice 
on SFD
CCL2
TNF
IL6
Vascularizaon
M1
M2
Monocytes
CCR2+
Monocytes
CCR2-
Blood vessel
Adipocyte
T lymphocyte
Cytokines
Figure 7 PTX3 deficiency protects from HFD-induced obesity. PTX3 deficiency associates with less pronounced visceral adipose tissue hypertrophy.
This effect is associated with increased vascularization, decreased infiltration of pro-inflammatory monocytes and macrophages.
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C1q, thus dampening its activity.57 Of note C1q was shown to modulate
macrophage polarization towards M2 phenotype independently from
complement activation.58 These findings suggest to further explore
whether, at the molecular level, the effect of PTX3 could be the conse-
quence of the modulation of soluble factors such as C1q, directly impli-
cated in macrophage polarization.
Considering that PTX3 shares a 82% sequence similarity between
mouse and man,7 we next investigated whether the findings in animal
models might be translated to humans.
We extend previous findings showing that PTX3 plasma levels mark
the immunoinflammatory response associated to obesity,26 by demon-
strating that specific genetic settings which were found to alter PTX3
plasma levels in Ghanaian women32 and in lung-transplant recipients
with primary graft dysfunction33 result in significant lower body mass
index and reduced visceral fat accumulation, further suggesting a direct
connection between lower genetically determined PTX3 plasma levels
and improved metabolic profile in humans.
These data, together with the observation in animal models, indicate
that PTX3 might contribute to obesity development by limiting adipose
tissue vascularization and promoting macrophage infiltration. As a conse-
quence, although the inhibition of PTX3 might be beneficial for the treat-
ment of obesity, the other protective effects associated to PTX331,48
suggest the need for the development of tissue selective PTX3 targeting
strategies to fully exploit its pharmacological potential.
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